Additional file 6 of Immune cell senescence drives responsiveness to immunotherapy in melanoma

Supplementary Material 6. Figure S6: GLF16+ (senescent) cell % percentages of immune subsets of Rs and NRs melanoma patients. a. Workflow depicting cellular senescence assessment in circulating CD4+ and CD8+ T-cells and B-cells (CD19+/CD20+) from melanoma patients by applying the senescence detecting algorithm (SDA). b-c. Representative dot plots from 4 melanoma patients, showing the percentages of GLF16+ cells (in insets) in CD4+ and CD8+ T-cells, and B-cells (CD19+/CD20+) isolated from two Rs (Responder 1 and 2) (b) and two NRs (Non-Responder 1 and 2) (c). Human and vessel icons were provided by Servier Medical Art (https://smart.servier.com/), licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).”